Aldeyra Therapeutics
ALDX
84 hedge funds and large institutions have $61.1M invested in Aldeyra Therapeutics in 2020 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 18 closing their positions.
354% more call options, than puts
Call options by funds: $454K | Put options by funds: $100K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
47% more capital invested
Capital invested by funds: $41.4M → $61.1M (+$19.7M)
17% more funds holding
Funds holding: 72 → 84 (+12)
7.37% less ownership
Funds ownership: 56.54% → 49.17% (-7.4%)
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$3.65M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.25M |
| 3 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
+$964K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$950K |
| 5 |
Morgan Stanley
New York
|
+$789K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.13M |
| 2 |
6CM
683 Capital Management
New York
|
-$2.78M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.64M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.17M |
| 5 |
Renaissance Technologies
New York
|
-$1.89M |
ALDX Hedge Fund Activity: Q2 2020 in Review
84 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2020, worth a combined $61.1M — up 47% from $41.4M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ALDX positions and 18 closed out — a net gain of 12 holders — while 19 added to existing stakes and 26 trimmed.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $3.65M. The largest seller was BlackRock, cutting an estimated $4.13M.
- 84 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2020, up from 72 in Q1 2020.
- Funds reported $61.1M of Aldeyra Therapeutics stock for Q2 2020, up 47% quarter-over-quarter.
- 30 funds opened new Aldeyra Therapeutics positions in Q2 2020 and 18 closed out, a net change of +12 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2020 was Ghost Tree Capital, an estimated $3.65M added.
- The largest Aldeyra Therapeutics seller in Q2 2020 was BlackRock, an estimated $4.13M sold.
Based on aggregated 13F filings for Q2 2020.